Medtronic HVAD™ System Advanced Heart Failure Management

The Medtronic HVAD System is a full-support, durable ventricular assist device (VAD) that is FDA approved for the less-invasive thoracotomy approach, destination therapy, and bridge to transplant.

Sign Up for Updates


Discover Why HVAD

Over the last 10 years, the HVAD System has been implanted in more than 18,000 patients worldwide.1

Product Design

Engineered for reliability and durability, the HVAD™ Pump is the world’s smallest commercially available, full-support, centrifugal VAD. Unique to the HVAD System is smart technology that enables clinicians to access and download data to gain insights into the pump’s performance. Autologs™ 1.3, the latest update to our advanced device management service, provides clinicians with faster access to important pump data, and deeper insights into the chronology of events.

Medtronic HVAD Pump on light blue background

Device Features  

30% smaller than other devices1
20% lighter than other devices1
38% less displaced volume1

Medtronic patient Al, living with the HVAD system since 2018


Living with the
HVAD System
since 2018

Surgical Versatility

Less-invasive  Thoracotomy Approach

The HVAD System was the first LVAD approved for the less-invasive thoracotomy approach, and it is also the only full-support, durable VAD with clinical evidence to prove its safety and effectiveness when used in a thoracotomy approach. HVAD implantation via the less-invasive thoracotomy approach has resulted in improved quality of life, reduced adverse events, and an unprecedented survival rate.2,3

View Brochure

Clinical Evidence

Revolve Data

The Registry to Evaluate the HeartWare Left Ventricular Assist System (ReVOLVE) was a multicenter registry that collected post-CE-mark clinical data on patients implanted with the HVAD System as a bridge to transplant (BTT). It demonstrated extended survival on the HVAD System:

  • 89% freedom from disabling stroke at six years4
  • 82% freedom from any stroke at six years4
  • 51% survival at seven years4

Thoracotomy Data

A recent analysis found that HVAD implantation via the less-invasive thoracotomy approach resulted in:

  • 30% relative reduction in length of stay compared to sternotomy approach2
  • An absolute average reduction in cost of more than $50,000 compared to sternotomy approach5

The latest clinical evidence from the HVAD LATERAL Trial demonstrated a significant improvement in quality of life: 

  • 95% freedom from debilitating stroke3
  • 30% reduced length of stay2 
  • 87% unprecedented survival at 2 years2

Additional Resources

HVAD Features and Benefits

Learn more about the features and benefits of the HVAD System.

Download Brochure

Education And Training Resources

Register or log in to Medtronic Academy.

Access Now
HVAD product image on a grey background

HVAD Enhanced

Discover new enhancements to the HVAD System.

Discover HVAD

Contact Information

24-hour Clinical Support

United States



Data extrapolated based on source data from: HVAD System Instructions for Use. HeartWare Inc., Miami Lakes, MA, USA. July 2018. Left Ventricular Assist System, Instructions for Use. Thoratec Corporation, Pleasanton, CA, USA. October 2017.


McGee E Jr, Danter M, Strueber M, et al. Evaluation of a lateral thoracotomy implant approach for a centrifugal-flow left ventricular assist device: The LATERAL clinical trial. J Heart Lung Transplant. April 2019;38(4):344-351.


Wieselthaler G, et al. Temporal Adverse Event Profile following LVAD Implantation via a Thoracotomy Approach: 2 Year Follow-up of the LATERAL Trial. Presented at ASAIO 2019; San Francisco, CA.


Zimpfer D, Fiane AE, Larbalestier R, et al. Long-Term Survival of Patients With Advanced Heart Failure Receiving an Left Ventricular Assist Device Intended as a Bridge to Transplantation: The Registry to Evaluate the HeartWare Left Ventricular Assist System. Circ Heart Fail. March 2020;13(3):e006252.


Mokadam NA, McGee E, Wieselthaler G, et al. Cost of Thoracotomy Approach: An Analysis of the LATERAL Trial. Ann Thorac Surg. November 2020;110(5):1512-1519.